Prostate-specific antigen (PSA) is an active serine protease, 1,2 the proteolytic activity of which in blood is inhibited by the formation of irreversible complexes with serum protease inhibitors such as α 1 -antichymotrypsin (α 1 -ACT), α 2 -macroglobulin (α 2 -M), and other acute-phase proteins. 3, 4 Besides these complexes, about 30% of the PSA are present in the free form. Elevated concentrations of PSA in serum are generally indicative of a pathologic condition of the prostate, including prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa). 5 Meanwhile, the ratio of free PSA (fPSA) to total PSA (tPSA) is used as an aid in distinguishing PCa from BPH. Here, we present some reversed ratios of fPSA to tPSA and study the possible reason for the reversed ratios. 
| MATERIALS AND METHODS

| RESULTS
Using Abbott Architect i2000, four of the reversed ratios maintained a ratio >1, one result changed into a ratio <1, and three got no results due to restricted conditions. With Cobas e602, seven of the results turned into a ratio <1, which was more reasonable and fit the patients' state better, and one kept a ratio >1, but the values of its fPSA and tPSA both reached their lower limit (Table 1) . We also evaluated the percentage of fPSA of another results demonstrated correlations and no reversed ratios occurred (Table S1 ).
| DISCUSSION
All these three detecting systems apply a two-site immunoenzymatic assay. Considering the instructions the manufacturers offered, the only possible reason for the Access inversion phenomenon was the presence of heterophile antibodies. Of the two-site immunoenzymatic assay Access applies, burro anti-goat, goat anti-biotin, and biotinylated mouse monoclonal anti-PSA antibodies are used to coat paramagnetic particles in fPSA testing, but tPSA testing only use mouse monoclonal anti-PSA antibody to coat. After exposed to animals or having received immunotherapy, heterophile antibodies such as human anti-goat, antiburro, anti-biotin antibodies may be present in patients' samples and then falsely elevated the value of fPSA, even to a level higher than tPSA. In one of the case using Cobas e602, a ratio >1 was obtained, since the lower limits of tPSA and fPSA were 0.003 ng/mL and 0.01 ng/mL, and therefore, it cannot be stated that tPSA is lower than fPSA.
| CONCLUSION
This study has clearly stated the existence of the reversed fPSA to tPSA ratio, but it has some limitations. The number of included cases is relatively small, and the research is unicentric. Detection methods should be performed within a time span conforming to analyte stability. In this study, the PSA instruments were in three different hospi- tPSA, total prostate-specific antigen; fPSA, free prostate-specific antigen. UniCel DxI800: UniCel DxI800 Access Immunoassay System (Beckman Coulter Inc, Brea, CA, USA); Abbott Architect i2000: Abbott Architect i2000 Immunoassay Analyser (Abbott Laboratories, Wiesbaden, Germany); Cobas e601: Cobas e601 (Roche Diagnostics GmbH, Mannheim, Germany).
T A B L E 1 Comparison of the different prostate-specific antigen testing results using three testing systems
